Evidence map›Paper›PMID 36277207›Full record

ArticleFrontiers in physiology2022

Hyperhomocysteinemia exacerbates acute kidney injury

Mei Zhang, Rong Dong, Jingjing Da, Jing Yuan, Yan Zha, Yanjun Long

Open access · goldAbstract read
In one paragraph

Article in Frontiers in physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mei ZhangDepartment of Nephrology, Guizhou Provincial Institute of Nephritic & Urinary Disease, Guizhou Provincial People's Hospital, Guiyang, China.
Rong DongDepartment of Nephrology, Guizhou Provincial Institute of Nephritic & Urinary Disease, Guizhou Provincial People's Hospital, Guiyang, China.
Jingjing DaDepartment of Nephrology, Guizhou Provincial Institute of Nephritic & Urinary Disease, Guizhou Provincial People's Hospital, Guiyang, China.
Jing YuanDepartment of Nephrology, Guizhou Provincial Institute of Nephritic & Urinary Disease, Guizhou Provincial People's Hospital, Guiyang, China.
Yan ZhaDepartment of Nephrology, Guizhou Provincial Institute of Nephritic & Urinary Disease, Guizhou Provincial People's Hospital, Guiyang, China.
Yanjun LongDepartment of Nephrology, Guizhou Provincial Institute of Nephritic & Urinary Disease, Guizhou Provincial People's Hospital, Guiyang, China.
Guizhou Provincial People's Hospital · CNGuizhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute kidney injury (AKI) is a complex and common set of multifactorial clinical syndromes, and associated with increased in-hospital mortality. There is increasing evidence that Hyperhomocysteinemia (HHcy) is highly associated with the development of a variety of kidney diseases, including AKI. However, the pathogenesis of HHcy in AKI remains unclear. In this study, we investigated the effect and mechanism of HHcy on cisplatin-induced AKI in mice and NRK-52E cells cultured with HHcy. We confirmed that mice with HHcy had higher serum levels of creatinine and more severe renal tubule injury after cisplatin injection. We found that HHcy aggravated renal mitochondrial damage, mainly manifested as decreased ATP β, significantly increased cytoplasmic Cyt C expression and the ADP/ATP ratio, and a significantly decreased mitochondrial DNA (mtDNA) copy number. In addition, we found that HHcy accelerated cisplatin-induced renal DNA damage; culturing NRK-52E cells with homocysteine (Hcy) could significantly increase apoptosis and mitochondrial damage. Interestingly, we found that Mdivi-1 reduced Hcy-induced mitochondrial damage, thereby reducing the level of apoptosis. In conclusion, these results suggest that HHcy might aggravate the development of AKI by increasing mitochondrial damage and that reducing Hcy levels or inhibiting mitochondrial damage may be a potential therapeutic strategy to delay the development of AKI.

Indexed as

acute kidney injuryapoptosisDNA damageHyperhomocysteinemiamitochondrial damage

Identifiers

PMID36277207
PMCPMC9581205
OpenAlexW4302283939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.